Suppr超能文献

聚(ADP-核糖)驱动帕金森病中病理性α-突触核蛋白神经变性。

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.

机构信息

Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

出版信息

Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat8407.

Abstract

The pathologic accumulation and aggregation of α-synuclein (α-syn) underlies Parkinson's disease (PD). The molecular mechanisms by which pathologic α-syn causes neurodegeneration in PD are not known. Here, we found that pathologic α-syn activates poly(adenosine 5'-diphosphate-ribose) (PAR) polymerase-1 (PARP-1), and PAR generation accelerates the formation of pathologic α-syn, resulting in cell death via parthanatos. PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α-syn to a more toxic strain. PAR levels were increased in the cerebrospinal fluid and brains of patients with PD, suggesting that PARP activation plays a role in PD pathogenesis. Thus, strategies aimed at inhibiting PARP-1 activation could hold promise as a disease-modifying therapy to prevent the loss of dopamine neurons in PD.

摘要

病理性α-突触核蛋白(α-syn)的积累和聚集是帕金森病(PD)的基础。病理性α-syn 导致 PD 神经退行性变的分子机制尚不清楚。在这里,我们发现病理性α-syn 激活聚(腺苷二磷酸核糖)(PAR)聚合酶 1(PARP-1),PAR 的生成加速了病理性α-syn 的形成,导致通过 parthanatos 发生细胞死亡。PARP 抑制剂或 PARP-1 的基因缺失可预防病理性α-syn 毒性。在正反馈回路中,PAR 将病理性α-syn 转化为更具毒性的菌株。PD 患者的脑脊液和大脑中 PAR 水平升高,提示 PARP 激活在 PD 发病机制中起作用。因此,旨在抑制 PARP-1 激活的策略可能有望成为一种疾病修饰疗法,以防止 PD 中多巴胺神经元的丧失。

相似文献

1
Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.
Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat8407.
2
PARP Inhibitors and Parkinson's Disease.
N Engl J Med. 2019 Jan 31;380(5):492-494. doi: 10.1056/NEJMcibr1814680.
3
PARkinson's: From cellular mechanisms to potential therapeutics.
Pharmacol Ther. 2022 Feb;230:107968. doi: 10.1016/j.pharmthera.2021.107968. Epub 2021 Aug 12.
4
Poly (ADP-ribose) in the pathogenesis of Parkinson's disease.
BMB Rep. 2014 Aug;47(8):424-32. doi: 10.5483/bmbrep.2014.47.8.119.
5
PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.124519.
6
PARIS undergoes liquid-liquid phase separation and poly(ADP-ribose)-mediated solidification.
EMBO Rep. 2023 Nov 6;24(11):e56166. doi: 10.15252/embr.202256166. Epub 2023 Oct 23.
7
Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein.
Nat Commun. 2024 May 31;15(1):4663. doi: 10.1038/s41467-024-49016-3.
9
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
J Clin Invest. 2014 Jul;124(7):3032-46. doi: 10.1172/JCI72176. Epub 2014 May 27.

引用本文的文献

2
Selective resilience in brain aging: challenging the scope of the disposable soma theory.
Biogerontology. 2025 Aug 1;26(4):152. doi: 10.1007/s10522-025-10292-1.
3
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications.
J Hematol Oncol. 2025 Jul 30;18(1):77. doi: 10.1186/s13045-025-01726-x.
6
Transient Poly(ADP-Ribose) Triggers FUS Condensation Hysteresis via a Prion-Like Mechanism.
bioRxiv. 2025 Jul 5:2025.07.03.659157. doi: 10.1101/2025.07.03.659157.
9
Adenosine diphosphate-ribosylation greatly affects proteins function: a focus on neurodegenerative diseases.
Front Aging Neurosci. 2025 Apr 30;17:1575204. doi: 10.3389/fnagi.2025.1575204. eCollection 2025.

本文引用的文献

1
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23.
3
Prying into the Prion Hypothesis for Parkinson's Disease.
J Neurosci. 2017 Oct 11;37(41):9808-9818. doi: 10.1523/JNEUROSCI.1788-16.2017.
4
Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Neurobiol Dis. 2018 Jan;109(Pt B):209-218. doi: 10.1016/j.nbd.2017.07.018. Epub 2017 Jul 24.
5
PARP inhibitors: Synthetic lethality in the clinic.
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
6
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26.
7
Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics.
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:437-454. doi: 10.1146/annurev-pharmtox-010716-105001.
10
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.
Science. 2016 Sep 30;353(6307). doi: 10.1126/science.aah3374.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验